Introduction
============

Hepatitis C virus (HCV) is a Hepacivirus of the Flaviviridae family, mainly involved in hepatic disorders, including chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC) \[[@B1]\].

HCV has also been recognized as the major etiologic factor of type II mixed cryoglobulinemia (MC), an autoimmune disease ultimately leading to B cell non-Hodgkin's lymphoma (NHL) in about 10% of MC patients \[[@B2]-[@B5]\].

The clonal B cell expansion is characterized by the production of an Ig molecule expressing a unique combination of antigen-specific sequences, the so called idiotype (Id). Therefore, the Id can be a suitable target for active, as well as passive immune-therapeutic strategies to eliminate the B cells driving the tumor \[[@B6],[@B7]\].

In this respect, the IGKV3-20 idiotype has been selected as a potential target of either passive immune therapy or active vaccine strategy \[[@B8]\].

We have previously reported the results of the effect of the IGKV3-20 candidate idiotype vaccine on *ex vivo* stimulated PBMCs, as experimental platform for evaluation and prediction of responsiveness to vaccination \[[@B9]\]. IGKV3-20 light chain protein has been shown to induce activation of circulating APCs, i.e., CD14^+^ monocytes, as well as CD123^+^ plasmacytoid dendritic cells (pDCs) and CD11c^+^ myeloid DCs (mDCs), in both HCV-positive and HCV-negative healthy control subjects, with production of Th2-type cytokines \[[@B9],[@B10]\]. No significant difference was observed between results obtained in human monocyte-derived dendritic cells (MDDCs) and circulating APCs, confirming previous results by us and other groups \[[@B11]-[@B15]\].

Moreover, such a candidate idiotype vaccine induces an early expression pattern, characterized by the induction of genes related to inflammatory response, and a late pattern, characterized by the induction of genes related to a B cell response \[[@B10]\].

Indeed, the Ingenuity Pathways Analysis (IPA) performed on "early" and "late" up-regulated genes showed a prevalence of inflammation and innate immunity-related pathways activated at 24 h post-induction, with significant overlapping between HCV-negative and positive groups, and a prevalence of "atypical" immune pathways activated at 6 days post-induction \[[@B10]\].

Nonetheless, some HCV-positive and negative subjects showed a poor response to the IGKV3-20 protein, with significant low levels of cytokine production and limited gene expression pattern.

In this regard, here we describe a systems biology approach to evaluate the individual responsiveness to the recombinant IGKV3-20 protein, aiming at identifying a possible impairment in the immune response and/or markers of responsiveness to such a specific antigen. Indeed, the specific effect of the recombinant IGKV3-20 protein has been evaluated *ex vivo* on human PBMCs of individual HCV-positive subjects via multiparametric analyses, including gene expression profiling combined to multiplex analysis of cytokines.

Materials and methods
=====================

Clinical specimens and cell treatment
-------------------------------------

Overall, samples from six HCV-positive subjects were analysed for the present study. Samples from five healthy donors were used as controls. Enrollment of subjects and treatment of derived human PBMCs have been previously described \[[@B10]\].

Unsupervised analysis
---------------------

For the unsupervised analysis a low-stringency filtering was applied, selecting the genes differentially expressed in 80% of all experiments with a \>3 fold change ratio in at least one experiment. Hierarchical cluster analysis was conducted on the selected genes according to Eisen et al. \[[@B16]\]; differentially expressed genes were visualized by Treeview and displayed according to the central method \[[@B16],[@B17]\].

Supervised analysis
-------------------

Supervised class comparison was performed using BRB ArrayTool developed at NCI, Biometric Research Branch, Division of Cancer Treatment and Diagnosis. Two subsets of genes were explored. The first subset included genes up-regulated in stimulated (IGKV3-20 treated) PBMCs compared to non-stimulated (PBS treated) PBMCs after 24 h incubation; the second subset included genes up-regulated in stimulated PBMCs compared to non-stimulated PBMCs after 6 days incubation.

Class comparison analyses were tested for an univariate significance threshold set at a *p-*value \< 0.001. Gene clusters identified by the univariate *t*-test were challenged with two alternative additional tests, an univariate permutation test (PT) and a global multivariate PT.

Class comparison and hierarchical clustering were employed to determine the pattern of response and results are illustrated as a heat map of significance values. All analyses were performed using R and Cytoscape (<http://www.cytoscape.org>). Gene function was assigned based on Database for Annotation, Visualization and Integrated Discovery (DAVID) (<http://david.abcc.ncifcrf.gov>) and Gene Ontology (<http://www.geneontology.org>).

Ingenuity Pathways Analysis (IPA,<http://www.ingenuity.com>) was employed to elucidate the relationship and connection between differentially expressed genes.

Results
=======

Cytokine pattern induced in circulating APCs
--------------------------------------------

PBMCs obtained from enrolled subjects were incubated with IGKV3-20 for 24 h and 6 days and, at each time-point, levels of Th1 (IL-2 and TNF-α) and Th2 (IL-5, IL-6 and IL-10) cytokines were assessed by ELISA in the culture supernatant. The results show that the stimulation induces a significant production of both Th1 (TNF-α) and Th2 cytokines (IL-6 and IL-10) with a prevalent Th2-biased cytokine pattern, as previously reported \[[@B10]\].

However, specific subjects show levels of cytokine induction significantly far from the mean value, indicating that differences may be observed in the response elicited by the antigen (Figure [1](#F1){ref-type="fig"}).

![**Analysis of cytokine production in supernatant of PBMCs.** The cytokine profile induced by IGKV3-20 after 24 h **(A)** and 6d **(B)** incubation was evaluated in supernatant of stimulated PBMCs.](1479-5876-12-11-1){#F1}

Indeed, at 24 h post-induction, PBMCs of subject DN always score at the top for release of TNF-α, IL-6 and IL-10 (1.7, 1.2 and 2.1 folds over the average, respectively). PBMCs of subject BE show a very similar pattern for TNF-α and IL-6 (1.8 and 1.2 folds over the average, respectively), whereas the amount of IL-10 released is the lowest (0.2 folds over the average). On the contrary, PBMCs of subjects MML and BD release the lowest levels of TNF-α and IL-6 (0.4 and 0.8 folds over the average, respectively) (Figure [1](#F1){ref-type="fig"}A).

Overall, high levels of IL-6 persist for the 6 days of induction, whereas the induction of IL-10 and, even more, TNF-α fades away at 6 days (Figure [1](#F1){ref-type="fig"}B).

Nevertheless, only PBMCs of subject BE (unlike those of DN) are confirmed to release the highest amount of TNF-α and IL-6, while PBMCs of subject VA release the highest amount of IL-10 (Figure [1](#F1){ref-type="fig"}B). As for the 24 h time-point, PBMCs of MML are confirmed to release the lowest amount of all three cytokines (Figure [1](#F1){ref-type="fig"}B). The overall results, therefore, indicate distinct cytokine patterns elicited by the same antigen *ex vivo* which may possibly reflect differences in individual response to the same antigen after *in vivo* vaccination.

Identification of immune response pattern to IGKV3-20 at "early" time-point
---------------------------------------------------------------------------

Subsequently, the gene expression profile of samples from HCV-positive subjects, previously analyzed as whole group \[[@B10]\], was evaluated to identify individual patterns induced by recombinant IGKV3-20 on PBMCs from six HCV-positive subjects. To this aim, a supervised pair-wise comparison was performed between stimulated (IGKV3-20 treated) and non-stimulated (PBS) PBMCs.

The analysis at 24 h identified a clustering confirming the different response of samples BE (high) and MML (low) observed in the pattern of cytokine production induced by IGKV3-20 stimulation.

In particular, 394 genes differentially expressed were overall identified (201 up-regulated genes and 193 down-regulated genes) with the strongest gene activation induced in PBMCs of subject BE and the weakest one induced in PBMCs of subject MML (Figure [2](#F2){ref-type="fig"}). The remaining 4 samples showed an intermediate transcriptional pattern, suggesting the possible identification of high vs. weak responders according to results of simultaneous gene expression data. A list of modulated genes correlated with immunology functions is shown in Table [1](#T1){ref-type="table"}.

![**Supervised analysis based on IGKV3-20 induction at 24 h.** Heat map of gene sets differentially modulated by IGKV3-20 after 24 h. The heat map in **(A)** shows several genes whose expression is strongly up-regulated in PBMCs of BE. The heat map in **(B)** shows several genes whose expression is down-regulated in PBMCs of MML after IGKV3-20 stimulation. Genes highlighted in yellow are mostly activated in sample BE. Genes highlighted in blue are activated in all HCV-positive samples, with exception of MML.](1479-5876-12-11-2){#F2}

###### 

Immunology genes modulated by IGKV3-20 at 24 h

  **Gene ID**   **Gene symbol**   **Gene name**                                            **Gene ID**   **Gene symbol**   **Gene name**
  ------------- ----------------- -------------------------------------------------------- ------------- ----------------- ---------------------------------------------------------------------------------
  7960947       A2M               Alpha-2-macroglobulin                                    8154733       ACO1              Aconitase 1, soluble
  8093294       CCR2              Chemokine receptor 2                                     8071899       ADORA2A           Adenosine A2a receptor
  7937508       CD151             CD151 molecule                                           7990818       BCL2A1            BCL2-related protein A1
  8133876       CD36              CD36 molecule                                            8089771       CD80              CD80 molecule
  7953428       CD4               CD4 molecule                                             7898655       CDA               Cytidine deaminase
  8115147       CD74              MHC, class II invariant chain                            8042942       HK2               Hexokinase 2
  8082035       CD86              CD86 molecule                                            8025601       ICAM1             Intercellular adhesion mol. 1
  7966089       CMKLR1            Chemokine-like receptor 1                                8097553       IL15              Interleukin 15
  8115076       CSF1R             Colonystimul. factor 1 recep.                            8054712       IL1A              Interleukin 1, alpha
  8065403       CST3              Cystatin C                                               8054722       IL1B              Interleukin 1, beta
  8166730       CYBB              Cytochrome b-245, beta polypeptide                       8044574       IL1RN             Interleukin 1 receptor antagonist
  8108370       EGR1              Early growth response 1                                  7931914       IL2RA             Interleukin 2 receptor, alpha
  7985268       FAH               Fumarylacetoacetate hydrolase                            8131803       IL6               Interleukin 6
  816502        FBP1              Fructose-1,6-bisphosphatase 1                            8077786       IRAK2             IL1 receptor-ass. kinase 2
  8165011       FCN1              Ficolin 1                                                8035351       JAK3              Janus kinase 3
  8058765       FN1               Fibronectin 1                                            7973336       MMP14             Matrix metallpeptidase 14
  7913694       FUCA1             Fucosidase, alpha-L-1, tissue                            7951217       MMP7              Matrix metallopeptidase 7
  8129974       FUCA2             Fucosidase, alpha-L-2, plasma                            8172220       NDP               Norrie disease
  8163908       GGTA1             Glycoprotein, alpha-galactosyltransferase 1 pseudogene   7930074       NFKB2             Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
  8180346       GPX1              Glutathione peroxidase 1                                 8075316       OSM               Oncostatin M
  8157582       GSN               Gelsonlin                                                8062927       PI3               Peptidase inhibitor 3
  7941936       GSTP1             Glutathione S-transferase pi 1                           8150509       PLAT              Plasmin. activator, tissue
  8140556       HGF               Hepatocyte growth factor                                 8037775       PTGIR             Prostagladin I2 receptor (IP)
  8180086       HLA-DMA           MHC, class II, DM alpha                                  7922976       PTGS2             Prostag-endoperox synthase 2
  8180078       HLA-DMB           MHC, class II, DM beta                                   7977786       SLC7A7            Solute carrier fam 7, memb 7
  8180100       HLA-DPA1          MHC, class II, DP alpha 1                                8130556       SOD2              Superoxide dismutase 2
  8179519       HLA-DPB1          MHC, class II, DP beta 1                                 8066214       TGM2              Transglutaminase 2
  8179481       HLA-DRA           MHC, class II, DR alpha                                  8045688       TNFAIP6           TNF, alpha-induced protein 6
  8058552       IDH1              Isocitrate dehydrognase 1                                7897877       TNFRSF1B          TNF receptor superfam, 1B
  7942300       IL18BP            Interleukin 18 binding protein                           7912145       TNFRSF9           TNF rec. superfam, memb 9
  8070826       ITGB2             Intergrin, beta 2                                        8163825       TRAF1             TNF receptor-assoc. factor 1
  8090162       ITGB5             Integrin, beta 5                                                                          
  7957023       LYZ               Lysozyme                                                                                  
  8127854       ME1               Malic enzyme 1                                                                            
  7926451       MRC1              Mannose receptor, C type 1                                                                
  8149448       MSR1              Macrophage scavenger recept 1                                                             
  8076403       NAGA              N-acetylgalactosaminidase, a                                                              
  8072744       NCF4              Neutrophil cytosolic factor 4                                                             
  8157650       PTGS1             Prostag-endoperoxsynthase 1                                                               
  7920271       S100A4            S100 calcium binding protein A4                                                           
  8136557       TBXAS1            Thromboxane A synthase 1                                                                  
  8157524       TLR4              Toll-like receptor 4                                                                      
  7924499       TLR5              Toll-like receptor 5                                                                      

Down-regulated (left) and up-regulated (right) genes.

The identified genes were further evaluated, to identify specific transcription profiles in the individual subjects. Considering the immune-related genes, heat maps in Figures [2](#F2){ref-type="fig"}A and B show a very strong up-regulation of specific genes mostly in sample BE (e.g., G0S2, VNN3, CCL18, TNFAIP6, IL-1A, CD80, TRAF1 and SNX9). An additional set of cytokine and cytokine receptor related genes, instead, shows a broad activation in all samples including BE (e.g., IL-1B, IL-6, IL-24, CCL23, CCL20 and IL2RA). The only exception is represented by the subject MML which shows a very limited pattern of gene activation and even down-regulation (Figure [2](#F2){ref-type="fig"}A and B).

Among the genes more strongly activated in BE, the TNF alpha-induced protein 6 (TNFAIP6), TNF receptor-associated factor 1 (TRAF1), G0/G1 switch gene 2 (G0S2), vanin-3 (VNN3) and sorting nexin 9 (SNX9) possibly suggest the activation of a TNF-mediated inflammatory pattern induced by IGKV3-20. Indeed, both TNFAIP6 and TRAF1 are downstream mediators of TNF signaling \[[@B18]\]\[[@B19]\], whereas G0S2 is known to be induced by TNF through the activation of the NFKB complex \[[@B20]\]. Moreover, SNX9 promotes internalization of TNFR \[[@B21]\], whereas VNN3 induction is mediated by Th17/Th1 type cytokines, including TNF-α \[[@B22]\].

Indeed, the pronounced pro-inflammatory pattern induced by IGKV3-20 in PBMCs of BE is more similar to the expression profile elicited in samples from healthy control subjects (Figure [3](#F3){ref-type="fig"}).

![**Supervised analysis based on IGKV3-20 induction at 24 h.** Heat map of gene sets differentially modulated by IGKV3-20 after 24 h, in HCV-positive (pink dots) and HCV-negative healthy control (blue dots) subjects. The dendrogram at the top of the matrix indicates the degree of similarity between samples.](1479-5876-12-11-3){#F3}

Furthermore, the strong up-regulation of CCL18 and CD80 molecules confirms the significant activation of circulating APCs by IGKV3-20 (Figures [2](#F2){ref-type="fig"}A and [3](#F3){ref-type="fig"}) \[[@B10]\].

On the other hand, PBMCs of subject MML show down-regulation of tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), a mediator of most of the metabolic effects of TNF-α, as well as of interleukin 1 receptor antagonist (IL1RN), whose expression is implicated in the modulation of the inflammasome (Figure [2](#F2){ref-type="fig"}A and B) \[[@B23]\]. This observation suggests the limited pro-inflammatory effect of TNF-α and IL-1 induced by IGKV3-20 in PBMCs of MML.

Furthermore, C-type lectin domain family 4 member D (CLEC4D), involved in antigen uptake for processing and further presentation to T cells, is strongly down-regulated in PBMCs of MML upon treatment with IGKV3-20, suggesting a possible impairment of the antigen uptake, processing and presentation pathway \[[@B24],[@B25]\].

Unexpectedly, CD274 molecule, which has been speculated to play a major role in suppressing the immune system during autoimmune disease and disease states, including hepatitis, is down-regulated by IGKV3-20 in PBMCs of MML while strongly up-regulated in all the other HCV-positive samples (Figure [2](#F2){ref-type="fig"}B) \[[@B26]\].

Identification of immune response pattern to IGKV3-20 at "late" time-point
--------------------------------------------------------------------------

To evaluate a change in the gene expression pattern over-time, the transcriptional profiling analysis was performed also after 6 days ("late") incubation (Figure [4](#F4){ref-type="fig"}).

![**Supervised analysis based on IGKV3-20 induction at 6d.** Heat map of gene sets differentially modulated by IGKV3-20 after 6 days. The heat map in **(A)** shows several genes whose expression is down-regulated in PBMCs of MML. The heat map in **(B)** shows several genes whose expression is strongly up-regulated in PBMCs of BE.](1479-5876-12-11-4){#F4}

The comparison analysis at this late time-point confirmed the different clustering of samples BE and MML. Overall, 105 genes differentially expressed were identified, of which 82 up-regulated and 23 down-regulated upon IGKV3-20 stimulation. A list of modulated genes correlated with immunology functions is shown in Table [2](#T2){ref-type="table"}. The number of differentially expressed genes at late time-point is drastically reduced compared to the early time-point, but it is still indicative of a late modulation of the immune response by IGKV3-20.

###### 

Immunology genes modulated by IGKV3-20 at 6 days

  **Gene ID**   **Gene symbol**   **Gene name**                                  **Gene ID**              **Gene symbol**   **Gene name**
  ------------- ----------------- ---------------------------------------------- ------------------------ ----------------- ---------------------------------------------------
  7960947       A2M               Alpha-2-macroglobulin                          8093294                  CCR2              Chemokine receptor 2
  8127854       ME1               Malic enzyme 1, NADP(+)-dependent, cytosolic   8063386                  CEBPB             CCAAT/enhancer binding protein (C/EBP), beta
  7948444       TCN1              Transcobalamin I                               8031374                  FCAR              Fc fragment of IgA, receptor for
                                                                                 7921873                  FCGR3A            Fc fragment of IgG, low affinity
                                                                                 Illa, receptor (CD16a)                     
                                                                                 8038899                  FPR1              Formly peptide receptor 1
                                                                                 8042942                  HK2               Hexokinase 2
                                                                                 8047086                  NAB1              NGFI-A binding protein 1 (EGR1 binding protein 1)
                                                                                 7920244                  S100A8            S100 calcium binding protein A8
                                                                                 7982597                  THBS1             Thrombospodin 1

Down-regulated (left) and up-regulated (right) genes.

Among the up-regulated genes CD300E, CLEC4D and FCAR are mostly activated in sample BE (Figure [4](#F4){ref-type="fig"}B). Moreover, several members of the leukocyte immunoglobulin-like receptor (LILR) family (i.e., LILRA1, LILRA3 and LILRA5) are activated, indicating a relevant role for such innate immune receptors, expressed on monocytes and B cells, in the response elicited by the IGKV3-20 (Figure [4](#F4){ref-type="fig"}A and B)\[[@B27]\].

Even at 6 days the expression pattern induced by IGKV3-20 in PBMCs of BE strongly resembles the expression profile elicited by the same antigen in a cohort of healthy control subjects, as indicated by the dendrogram at the top of matrix in Figure [5](#F5){ref-type="fig"}.

![**Supervised analysis based on IGKV3-20 induction at 6d.** Heat map of gene sets differentially modulated by IGKV3-20 after 6 days in HCV-positive (pink dots) and HCV-negative healthy control (blue dots) subjects. The dendrogram at the top of the matrix indicates the degree of similarity between samples.](1479-5876-12-11-5){#F5}

On the other hand, immune genes such as LILRA3, CXCL13, CRLF2 and CD82 are even down-regulated in sample MML, suggesting the inefficient delivery of co-stimulatory signals for the T cell receptor (TCR)/CD3 pathway for such a subject (Figure [4](#F4){ref-type="fig"}A) \[[@B28]\].

Identification of unique immune signatures in PBMCs of BE and MML
-----------------------------------------------------------------

A subsequent supervised analysis was performed individually comparing sample BE or MML to all the other samples, and such analysis included all genes modulated by IGKV3-20 without subtracting the basal expression patterns (i.e., PBS).

In regards to PBMCs of subject BE, overall 102 differentially expressed genes were identified at 24 h post stimulation, of which 62 up-regulated and 40 down-regulated genes (data not shown).

Among the up-regulated genes, several were identified as immunology genes and the resulting immunology network was visualized using Cytoscape (<http://www.cytoscape.org>) (Figure [6](#F6){ref-type="fig"}A).

![**Unique immune signatures induced in PBMCs of BE and MML.** Cytoscape analysis of immunology genes modulated by IGKV3-20 in PBMCs of BE at 24 h **(A)** and 6d **(B)**. Cytoscape analysis of immunology genes and killer cell receptor genes modulated by IGKV3-20 in PBMCs of MML at 24 h **(C)** and 6d **(D)**.](1479-5876-12-11-6){#F6}

At 6 days post stimulation, overall 617 differentially expressed genes were identified, of which 349 up-regulated and 268 down-regulated genes (data not shown). Interestingly, a unique gene signature was identified, characterized by the up-regulation of Th1 cytokine (i.e., TNF and IFNγ) and cytokine receptor (i.e., IL2RB, IL18R1 and IL12RB2) genes, as well as high-affinity Fc-gamma receptor genes (i.e., FCGR1A and FCGR1B) (Figure [6](#F6){ref-type="fig"}B). All these genes contribute to the inflammatory response, promoting proliferation of natural killer (NK) cells, as well as T-cells of the Th1 phenotype, strongly suggesting a loop of specific activation of the IFNγ signaling \[[@B29]\], confirmed also by the IPA analysis (Figure [7](#F7){ref-type="fig"}).

![**Ingenuity pathways analysis.** IFNγ signaling pathway uniquely activated in PBMCs of subject BE after 6 days stimulation with IGKV3-20.](1479-5876-12-11-7){#F7}

On the other hand, in PBMCs of subject MML, the analysis identified overall 479 differentially expressed genes at 24 h, whereas 122 genes were differentially expressed at 6 days (data not shown). However, marker genes of the immune response were not identified up-regulated and most of the identified genes were not even annotated.

Interestingly, several immunology and killer-cell-receptor genes (i.e., KLRD1, KLRB1, KLRF1, KIR2DL4, KIR2DS1) were found down-regulated (Figure [6](#F6){ref-type="fig"}C and D), suggesting a possible impairment of the NK cell function in such a subject \[[@B30]\].

The overall results suggest the identification of molecular markers of individual response to a specific antigen, which could represent a platform for the identification of common predictive signatures of response to vaccination.

Discussion
==========

A major challenge in vaccinology is to predict vaccine efficacy \[[@B31]-[@B33]\]. Here, we used a multiparametric systems biology approach to identify gene signatures predictive of an immune response, using an experimental platform based on PBMCs from 6 HCV-positive subjects stimulated *ex vivo* with the IGKV3-20 light-chain protein, as candidate idiotype vaccine.

The cytokine pattern induced by IGKV3-20 was assessed by ELISA in culture supernatant of stimulated PBMCs, after 24 h or 6 days of incubation (Figure [1](#F1){ref-type="fig"}).

The results show that the stimulation induces an overall significant production of both Th1 (TNF-α) and Th2 cytokines (IL-6 and IL-10), with a prevalence of the latters. However, specific samples consistently show very different levels of TNF-α and IL-6 production, which are highest for samples BE and DN and lowest for sample MML. These results, although based on a small cohort, indicate a significant difference in the individual response to the same antigen and, in particular, suggest that subject BE is characterized by a relevant pro-inflammatory pattern with the highest levels of IL-6 and TNF-α and the lowest level of the anti-inflammatory IL-10 (Figure [1](#F1){ref-type="fig"}).

The global gene expression profile of PBMCs stimulated with IGKV3-20 for 24 h and 6 days confirmed such strong differences between BE and MML.

Indeed, in agreement with the cytokine expression pattern, the sample from subject BE shows the highest number of strongly activated genes, whereas the sample from subject MML shows the weakest transcriptional profile (Figures [2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"}).

In particular, considering immune-related genes up-regulated at 24 h, the activation of a TNF-mediated inflammatory pattern in subject BE induced by IGKV3-20 is strongly suggested (Figure [2](#F2){ref-type="fig"}A). Moreover, the up-regulation of CCL18 and CD80 molecules suggests a significant activation of circulating APCs in this subject (Figure [2](#F2){ref-type="fig"}A). On the contrary, several immune-related genes are even down-regulated in PBMCs of MML, suggesting a possible impaired activation of a pro-inflammatory and/or immune response by the antigen.

The strong difference in transcriptional profile of immune-related genes between subjects BE and MML is confirmed also after 6 days of incubation with IGKV3-20 (Figure [4](#F4){ref-type="fig"}).

Indeed, BE shows the gene activation of several members of the LILR (i.e., LILRA1, LILRA3 and LILRA5) family of immunoreceptors, as well as CD300E, CLEC4D and FCAR (Figure [4](#F4){ref-type="fig"}A and B).

More importantly, the supervised analysis performed on the pool of genes modulated by IGKV3-20, without subtracting PBS pattern, identified a late transcriptional profile characterized by the up-regulation of TNF, IFNγ, IL2RB, IL18R1, IL12RB2, FCGR1A and FCGR1B genes (Figure [6](#F6){ref-type="fig"}B), which is unique for subject BE and suggestive of a possible Th1-polarization of the immune response.

In this respect, the pronounced pro-inflammatory pattern induced by IGKV3-20 in PBMCs of BE strongly resembles the expression profile elicited by the same antigen in a cohort of HCV-negative healthy control subjects, as indicated in Figures [3](#F3){ref-type="fig"} and [5](#F5){ref-type="fig"}.

On the contrary, a global down-regulation of immune genes such as killer cell receptor genes in PBMCs of MML may even suggest the inefficient establishment of NK cell-mediated innate immune response to the candidate idiotype vaccine.

Overall, the multiparametric analysis performed on PBMCs loaded *ex vivo* with the IGKV3-20 candidate idiotypic vaccine shows that the identification of specific gene transcriptional patterns to confirm differences in the immune response evaluated by means of different parameters (e.g., cytokine profile) is feasible.

Indeed, subjects BE and MML are clearly different regardless the parameters used to analyze the *ex vivo* effect of the IGKV3-20 on their PBMCs, suggesting a possible marked diversity of their responsiveness to such an antigen if administered *in vivo*.

In conclusion, the present study represents a proof of concept and larger cohort studies will be needed to validate the results. Nevertheless, our results strongly suggest that our *ex vivo* screening platform is potentially useful to identify "proficient" prediction markers of individual responsiveness to a specific antigen, or classes of antigens (e.g., peptides, proteins, DNA), as well as to guide optimization of vaccine design.

Moreover, systems biology approaches not only allows the scrutiny of a global picture of vaccine-induced immune effect but can be also used to uncover new correlates of vaccine efficacy \[[@B34]\].
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